MedPath

Zhejiang Kanglaite Pharmaceutical Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 4
1 (100.0%)

A Multicenter Real World Study of Kanglaite for Cancer Cachexia

Conditions
Cancer Cachexia
Interventions
Drug: Kanglaite Injection/Capsules
First Posted Date
2018-08-15
Last Posted Date
2018-08-21
Lead Sponsor
Zhejiang Kanglaite Pharmaceutical Co.Ltd
Target Recruit Count
100000
Registration Number
NCT03631459
Locations
🇨🇳

Peking University International Hospital, Beijing, Beijing, China

🇨🇳

NanJing PLA 81 Hospital, Nanjing, Jiangsu, China

A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia

Phase 4
Conditions
Cancer Cachexia
Interventions
Drug: Kanglaite Injection
First Posted Date
2015-09-17
Last Posted Date
2017-02-15
Lead Sponsor
Zhejiang Kanglaite Pharmaceutical Co.Ltd
Target Recruit Count
160
Registration Number
NCT02553187
Locations
🇨🇳

Cancer Center, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.